News

New research shows that the benefits of sodium-glucose cotransporter-2 (SGLT2) inhibitors on symptoms and quality of life in patients with heart failure extend to canagliflozin (Invokana, Invokamet, Janssen). Canagliflozin 100 mg daily bested placebo by a mean of 4.3 points for the primary outcome of 12-week change in the Kansas City Cardiomyopathy Questionnaire (KCCQ) total
0 Comments
The keynote address at the recent Nurse Practitioners in Women’s Health annual conference, given by Rear Admiral Susan Orsega, MSN, director of the Commissioned Corps Headquarters of the U.S. Public Health Service, focused on the role that women’s health nurse practitioners played in the COVID-19 pandemic, and identified the skills needed to better address women’s
0 Comments
A medical device delivering auditory and visual stimulation that evoke a particular brain wave pattern is an encouraging nonpharmacologic option to treat symptoms of Alzheimer’s Disease (AD), a new phase 2 proof-of-concept study suggests. “We showed daily gamma sensory stimulation is safe and well-tolerated, with beneficial effects in cognitive and functional abilities and a significant
0 Comments
In an observational study reported at CHEST 2021, the American College of Chest Physicians annual meeting, Hanan Ajay, a fifth-year medical student at the University of Liverpool in England, said that of 34 patients on azithromycin, nearly all had reduced infection rates compared with historical averages. In this exclusive MedPage Today video, Ajay is joined
0 Comments
Find the latest COVID-19 news and guidance in Medscape’s   Coronavirus Resource Center. The proportion of hypertensive patients with blood pressure control fell substantially in the United States during the COVID-19 pandemic, if the data from 24 health systems is representative of national trends. The decline in blood pressure control corresponded with – and might be
0 Comments
While many people fully recover from COVID-19 after overcoming the infection, some are left with symptoms that continue to persist way after battling the disease. This phenomenon has been baffling scientists and medical experts for months. But key findings are starting to shed light on what could really be causing long COVID.  What Is Long
0 Comments
A new formulation of bevacizumab for neovascular age-related macular degeneration (nAMD) is headed for evaluation by the US Food and Drug Administration (FDA) amid controversy about a phase 3 trial. FDA approval would set bevacizumab-vikg (Lytenava) apart from formulations from compounding pharmacies currently sold for off-label ophthalmic use, said Firas M. Rahhal, MD, an associate
0 Comments
Local community health workers in rural China successfully treated patients with hypertension, enabling more than half to reach normal blood pressures, in a new study involving almost 34,000 patients. In the study, local health workers (known as village doctors), most of whom had minimal formal medical education and were trained with a standard protocol that
0 Comments
On the basis of outcomes, there was no clear winner from a trial that directly compared two modern devices used in patients undergoing percutaneous left atrial appendage (LAA) closure. But the devices were not interchangeable for rates of complications or leaks, according to results of the open-label SWISS APERO trial, which compared the Amplatzer Amulet
0 Comments
Hepatic arterial infusion chemotherapy (HAIC) with FOLFOX led to superior patient outcomes and less toxicity than standard of care transarterial chemoembolization (TACE) for patients with large, unresectable hepatocellular carcinoma (HCC), a randomized, phase 3 trial has shown. In a group of 315 patients with unresectable tumors at least 7 cm in diameter and no macrovascular
0 Comments
Few rheumatoid arthritis patients whose initial experience with tumor necrosis factor (TNF) inhibitors was suboptimal achieved “low disease activity” status upon switching to another biologic, whether it was another TNF inhibitor or another class of drug, researchers found. Analysis of 939 patients in the registry database formerly known as Corrona (renamed CorEvitas earlier this year)
0 Comments
A novel noninvasive endoscopy trial lends further support for the safety of single antiplatelet therapy after a 6-month course of dual antiplatelet therapy (DAPT) in patients undergoing percutaneous coronary intervention (PCI). Results from the OPT-PEACE trial show that patients at low bleeding risk on aspirin or clopidogrel monotherapy for an additional 6 months after DAPT
0 Comments
NEW ORLEANS — Although still technically an orphan disease, hereditary angioedema (HAE) remains a popular focus for drug developers despite a half-dozen products already approved in the U.S. That was on full display at the American College of Allergy, Asthma and Immunology’s annual meeting here, with phase II studies on two investigational agents featured in
0 Comments
The general public may be misinterpreting mindfulness and missing out on its benefits, according to a new study. What to know: The practice of mindfulness has gained in popularity in recent years and has been shown to effectively reduce stress and help alleviate related health disorders. Mindfulness involves two steps for mitigating stressful situations: awareness
0 Comments